| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ANVSAnnovis Bio, Inc. | 84.81M | 3.20 | -0.00 | -189.15% | ||||
| CLNNClene Inc. | 60.19M | 5.11 | -0.90 | -47.71% | -142.5% | -17.38% | ||
| ABOSAcumen Pharmaceuticals, Inc. | 112.67M | 1.86 | -1.09 | -143.12% | 0.16 | |||
| BHVNBiohaven Ltd. | 1.58B | 11.92 | -1.28 | -198.83% | 0.09 | |||
| IKTInhibikase Therapeutics, Inc. | 200.09M | 1.65 | -1.42 | -100% | -65.37% | 0.00 | ||
| ALECAlector, Inc. | 198.66M | 1.82 | -1.48 | 3.6% | -156.03% | -186.68% | 0.34 | |
| CGTXCognition Therapeutics, Inc. | 121.82M | 1.38 | -1.62 | -76.61% | 0.04 | |||
| ATHEAlterity Therapeutics Limited | 60M | 3.31 | -2.90 | 35.32% | -330.63% | -73.75% | 0.00 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.61M | 1.05M | 27.52M | 955K | 814K | 853K | 200.58M | 53.91M | 91.37M | 135.16M |
| Revenue Growth % | -0.97% | -0.34% | 25.08% | -0.97% | -0.15% | 0.05% | 234.14% | -0.73% | 0.7% | 0.48% |
| Cost of Goods Sold | 58.44M | 119.53M | 134.55M | 101.18M | 50.84M | 74.88M | 0 | 0 | 0 | 0 |
| COGS % of Revenue | 36.37% | 113.3% | 4.89% | 105.95% | 62.45% | 87.79% | - | - | - | - |
| Gross Profit | -56.83M | -118.48M | -107.03M | -100.23M | -50.02M | -74.03M | 200.58M | 53.91M | 91.37M | 135.16M |
| Gross Margin % | -35.37% | -112.3% | -3.89% | -104.95% | -61.45% | -86.79% | 1% | 1% | 1% | 1% |
| Gross Profit Growth % | -5.58% | -1.08% | 0.1% | 0.06% | 0.5% | -0.48% | 3.71% | -0.73% | 0.7% | 0.48% |
| Operating Expenses | 81.54M | 160.59M | 182.77M | 143.66M | 35.67M | 38.7M | 128.6M | 185.46M | 282.41M | 289.72M |
| OpEx % of Revenue | 50.74% | 152.22% | 6.64% | 150.43% | 43.83% | 45.37% | 0.64% | 3.44% | 3.09% | 2.14% |
| Selling, General & Admin | 23.11M | 41.06M | 48.23M | 42.48M | 35.74M | 38.7M | 46.32M | 49.9M | 61.84M | 67.2M |
| SG&A % of Revenue | 14.38% | 38.92% | 1.75% | 44.48% | 43.9% | 45.37% | 0.23% | 0.93% | 0.68% | 0.5% |
| Research & Development | 58.44M | 119.53M | 134.55M | 101.18M | 50.84M | 75.09M | 82.28M | 135.56M | 220.57M | 222.52M |
| R&D % of Revenue | 36.37% | 113.3% | 4.89% | 105.95% | 62.45% | 88.03% | 0.41% | 2.51% | 2.41% | 1.65% |
| Other Operating Expenses | 26K | 571K | -2.35M | 2.74M | -50.9M | -75.09M | 0 | 0 | 0 | 0 |
| Operating Income | -79.94M | -159.53M | -155.25M | -158.85M | -85.7M | -112.73M | 71.97M | -131.56M | -191.04M | -154.56M |
| Operating Margin % | -49.74% | -151.22% | -5.64% | -166.34% | -105.28% | -132.16% | 0.36% | -2.44% | -2.09% | -1.14% |
| Operating Income Growth % | -11.02% | -1% | 0.03% | -0.02% | 0.46% | -0.32% | 1.64% | -2.83% | -0.45% | 0.19% |
| EBITDA | -79.13M | -157.11M | -152.19M | -155.64M | -84.13M | -111.22M | 73.09M | -130.81M | -190.11M | -153.67M |
| EBITDA Margin % | -49.24% | -148.92% | -5.53% | -162.97% | -103.36% | -130.39% | 0.36% | -2.43% | -2.08% | -1.14% |
| EBITDA Growth % | -12.4% | -0.99% | 0.03% | -0.02% | 0.46% | -0.32% | 1.66% | -2.79% | -0.45% | 0.19% |
| D&A (Non-Cash Add-back) | 806K | 2.43M | 3.07M | 3.22M | 1.56M | 1.51M | 1.11M | 744K | 928K | 893K |
| EBIT | -79.94M | -158.96M | -153.91M | -152.42M | -85.76M | -112.73M | 71.97M | -131.56M | -191.04M | -154.56M |
| Net Interest Income | 196K | 556K | -142K | 2.69M | 8.2M | 1.37M | 42K | 6.35M | 31.01M | 25.82M |
| Interest Income | 196K | 1.42M | 3.55M | 6.39M | 8.2M | 1.37M | 42K | 6.35M | 31.01M | 25.82M |
| Interest Expense | 0 | 863K | 3.69M | 3.7M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 26K | 571K | -2.35M | 2.74M | 8.4M | 1.87M | -54K | 5.95M | 30.56M | 25.63M |
| Pretax Income | -79.91M | -158.96M | -157.6M | -156.12M | -77.3M | -110.86M | 71.92M | -125.61M | -160.48M | -128.93M |
| Pretax Margin % | -49.73% | -150.68% | -5.73% | -163.47% | -94.96% | -129.97% | 0.36% | -2.33% | -1.76% | -0.95% |
| Income Tax | 701K | 1.14M | -4.37M | -470K | 379K | 283K | 4.95M | -8.66M | -13.45M | -6.62M |
| Effective Tax Rate % | 1.01% | 1.01% | 0.97% | 1% | 1% | 1% | 0.93% | 0.93% | 0.92% | 0.95% |
| Net Income | -80.61M | -160.11M | -153.24M | -155.65M | -77.68M | -111.14M | 66.97M | -116.95M | -147.03M | -122.31M |
| Net Margin % | -50.16% | -151.76% | -5.57% | -162.98% | -95.43% | -130.3% | 0.33% | -2.17% | -1.61% | -0.9% |
| Net Income Growth % | -10.27% | -0.99% | 0.04% | -0.02% | 0.5% | -0.43% | 1.6% | -2.75% | -0.26% | 0.17% |
| Net Income (Continuing) | -80.61M | -160.11M | -153.24M | -155.65M | -77.68M | -111.14M | 66.97M | -116.95M | -147.03M | -122.31M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.66 | -4.66 | -4.07 | -3.93 | -1.95 | -2.78 | 1.38 | -2.47 | -2.76 | -2.27 |
| EPS Growth % | -8.17% | -0.75% | 0.13% | 0.03% | 0.5% | -0.43% | 1.5% | -2.79% | -0.12% | 0.18% |
| EPS (Basic) | -2.66 | -4.66 | -4.07 | -3.93 | -1.95 | -2.78 | 1.51 | -2.47 | -2.76 | -2.27 |
| Diluted Shares Outstanding | 30.33M | 34.35M | 37.65M | 39.56M | 39.88M | 39.91M | 48.46M | 47.37M | 53.22M | 53.77M |
| Basic Shares Outstanding | 30.33M | 34.35M | 37.65M | 39.56M | 39.88M | 39.91M | 44.23M | 47.37M | 53.22M | 53.77M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 377.4M | 391.36M | 426.33M | 431.39M | 378.38M | 299.28M | 584.81M | 719.1M | 639.28M | 485.41M |
| Cash & Short-Term Investments | 370.59M | 386.92M | 417.62M | 427.66M | 375.72M | 295.38M | 579.09M | 710.41M | 618.83M | 471.39M |
| Cash Only | 370.59M | 386.92M | 417.62M | 427.66M | 375.72M | 295.38M | 579.09M | 710.41M | 618.83M | 471.39M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 509K | 178K | 240K | 2K | 68K | 15K | 13K | 62K | 5.16M | 0 |
| Days Sales Outstanding | 115.61 | 61.58 | 3.18 | 0.76 | 30.49 | 6.42 | 0.02 | 0.42 | 20.61 | - |
| Inventory | -509K | -178K | -240K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 1.35M | 766K | 1.71M | 3.49M | 1.17M |
| Total Non-Current Assets | 7.83M | 68.61M | 70M | 67.41M | 40.89M | 33.69M | 24.56M | 38.94M | 57.1M | 61.7M |
| Property, Plant & Equipment | 3.86M | 56.45M | 54.99M | 52.84M | 27.15M | 20.36M | 14.13M | 8.01M | 16M | 13.79M |
| Fixed Asset Turnover | 0.42x | 0.02x | 0.50x | 0.02x | 0.03x | 0.04x | 14.19x | 6.73x | 5.71x | 9.80x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 4.06M | 4.06M | 4.06M | 0 | 0 | 0 | 0 | 0 | 860K |
| Other Non-Current Assets | 1.12M | 6.25M | 6.9M | 4.87M | 3.79M | 1.69M | 3.35M | 12.72M | 7.21M | 3.81M |
| Total Assets | 385.24M | 459.98M | 496.33M | 498.8M | 419.27M | 332.98M | 609.37M | 758.03M | 696.38M | 547.11M |
| Asset Turnover | 0.00x | 0.00x | 0.06x | 0.00x | 0.00x | 0.00x | 0.33x | 0.07x | 0.13x | 0.25x |
| Asset Growth % | 0.27% | 0.19% | 0.08% | 0% | -0.16% | -0.21% | 0.83% | 0.24% | -0.08% | -0.21% |
| Total Current Liabilities | 22.22M | 41.08M | 37.37M | 14.93M | 17.71M | 25.85M | 33.45M | 50.15M | 56.89M | 48.5M |
| Accounts Payable | 4.52M | 13.07M | 13.63M | 1.47M | 1.24M | 4.12M | 3.69M | 9.27M | 25.39M | 7.77M |
| Days Payables Outstanding | 28.22 | 39.91 | 36.98 | 5.3 | 8.92 | 20.07 | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 284K | 363K | -857K | 1000K | 0 | 0 | 1000K | 1000K | 0 | 1000K |
| Other Current Liabilities | 804K | 1.87M | 1.72M | 837K | 322K | 516K | 405K | 503K | 2.13M | 29.27M |
| Current Ratio | 16.99x | 9.53x | 11.41x | 28.90x | 21.36x | 11.58x | 17.48x | 14.34x | 11.24x | 10.01x |
| Quick Ratio | 17.01x | 9.53x | 11.41x | 28.90x | 21.36x | 11.58x | 17.48x | 14.34x | 11.24x | 10.01x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 2.35M | 53.5M | 51.77M | 160.87M | 128.63M | 123.12M | 109.87M | 85.85M | 78.13M | 11.68M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 51.32M | 51.52M | 49.9M | 17.84M | 12.33M | 6.39M | 0 | 10.72M | 8.23M |
| Deferred Tax Liabilities | 0 | -2.08M | -254K | -49.9M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 2.35M | 2.18M | 254K | 110.97M | 553K | 553K | 553K | 553K | 0 | 0 |
| Total Liabilities | 24.57M | 94.57M | 89.14M | 175.8M | 146.35M | 148.97M | 143.32M | 135.99M | 135.02M | 60.18M |
| Total Debt | 0 | 51.32M | 52.25M | 51.55M | 22.94M | 17.84M | 12.33M | 6.47M | 11.84M | 10.84M |
| Net Debt | -370.59M | -335.6M | -365.37M | -376.11M | -352.78M | -277.54M | -566.77M | -703.93M | -607M | -460.55M |
| Debt / Equity | - | 0.14x | 0.13x | 0.16x | 0.08x | 0.10x | 0.03x | 0.01x | 0.02x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | 0.17x | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | -7.75x | - | - | - |
| Interest Coverage | - | -184.86x | -42.10x | -42.97x | - | - | - | - | - | - |
| Total Equity | 360.67M | 365.4M | 407.19M | 323M | 272.92M | 184.01M | 466.04M | 622.04M | 561.37M | 486.93M |
| Equity Growth % | 0.24% | 0.01% | 0.11% | -0.21% | -0.16% | -0.33% | 1.53% | 0.33% | -0.1% | -0.13% |
| Book Value per Share | 11.89 | 10.64 | 10.81 | 8.16 | 6.84 | 4.61 | 9.62 | 13.13 | 10.55 | 9.06 |
| Total Shareholders' Equity | 360.67M | 365.4M | 407.19M | 323M | 272.92M | 184.01M | 466.04M | 622.04M | 561.37M | 486.93M |
| Common Stock | 317K | 348K | 385K | 399K | 399K | 399K | 466K | 521K | 537K | 538K |
| Retained Earnings | -129.1M | -289.21M | -442.35M | -598M | -671.88M | -783.03M | -716.05M | -833M | -980.03M | -1.1B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -5.34M | -7.67M | -7.74M | -10.5M | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -62.45M | -117.27M | -131.18M | -28.28M | -52.97M | -80.36M | 92.61M | -108.82M | -133.91M | -150.05M |
| Operating CF Margin % | -38.86% | -111.16% | -4.77% | -29.61% | -65.07% | -94.21% | 0.46% | -2.02% | -1.47% | -1.11% |
| Operating CF Growth % | -90.44% | -0.88% | -0.12% | 0.78% | -0.87% | -0.52% | 2.15% | -2.18% | -0.23% | -0.12% |
| Net Income | -80.61M | -160.11M | -153.24M | -155.65M | -77.68M | -111.14M | 66.97M | -116.95M | -147.03M | -122.31M |
| Depreciation & Amortization | 806K | 2.43M | 3.07M | 3.22M | 6.82M | 1.51M | 1.11M | 744K | 928K | 893K |
| Stock-Based Compensation | 10.41M | 24.93M | 26.76M | 27.01M | 23.59M | 22.01M | 24.66M | 31.32M | 40.91M | 45.96M |
| Deferred Taxes | -963K | -3.25M | -2.2M | -1.59M | -1.25M | -1.69M | 4.57M | -11.13M | -15.69M | -9.35M |
| Other Non-Cash Items | -3.57M | -156K | 1.59M | 4.28M | 0 | 5.46M | 5.69M | 6M | 7.5M | 2.69M |
| Working Capital Changes | 11.47M | 18.89M | -7.16M | 94.45M | -4.45M | 3.48M | -10.4M | -18.8M | -20.53M | -67.94M |
| Change in Receivables | 1.25M | 331K | -62K | 238K | 0 | 53K | 15K | 0 | -5.16M | 5.16M |
| Change in Inventory | -356.12M | -346.92M | -396.2M | 9.6M | 0 | 0 | 0 | 0 | -8.9M | 0 |
| Change in Payables | 11.16M | 15.19M | 147K | -25.63M | -78K | 7.73M | -492K | 11.87M | 22.86M | -18.3M |
| Cash from Investing | -1.38M | -16.64M | -3.52M | -1.73M | -547K | -196K | -575K | -464K | -2.77M | -298K |
| Capital Expenditures | -1.38M | -16.64M | -3.63M | -1.77M | -555K | -196K | -575K | -464K | -2.81M | -298K |
| CapEx % of Revenue | 0.86% | 15.78% | 0.13% | 1.85% | 0.68% | 0.23% | 0% | 0.01% | 0.03% | 0% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 105K | 39K | 8K | 0 | 0 | 0 | 37K | 0 |
| Cash from Financing | 140.84M | 154.31M | 165.4M | 40.04M | 228K | 215K | 190.33M | 241.46M | 45.1M | 1.55M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 9.5M | 25.7M | 17.84M | 4.69M | 228K | 215K | 15.54M | 17.84M | 21.52M | 1.91M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -63.84M | -133.91M | -134.81M | -30.04M | -53.52M | -80.56M | 92.03M | -109.28M | -136.72M | -150.35M |
| FCF Margin % | -39.72% | -126.93% | -4.9% | -31.46% | -65.75% | -94.44% | 0.46% | -2.03% | -1.5% | -1.11% |
| FCF Growth % | -51.8% | -1.1% | -0.01% | 0.78% | -0.78% | -0.51% | 2.14% | -2.19% | -0.25% | -0.1% |
| FCF per Share | -2.11 | -3.90 | -3.58 | -0.76 | -1.34 | -2.02 | 1.90 | -2.31 | -2.57 | -2.80 |
| FCF Conversion (FCF/Net Income) | 0.77x | 0.73x | 0.86x | 0.18x | 0.68x | 0.72x | 1.38x | 0.93x | 0.91x | 1.23x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 442K | 575K | 294K | 0 | 1.58M | 1.37M | 580K | 2.66M | 1.55M | 3.17M |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -24.78% | -44.1% | -39.67% | -42.63% | -26.07% | -48.65% | 20.61% | -21.5% | -24.85% | -23.34% |
| Return on Invested Capital (ROIC) | - | -1203.55% | -325.18% | - | - | - | - | - | - | -439.41% |
| Gross Margin | -3536.53% | -11230.24% | -388.92% | -10495.08% | -6145.21% | -8678.9% | 100% | 100% | 100% | 100% |
| Net Margin | -5016.3% | -15176.11% | -556.84% | -16297.91% | -9542.63% | -13029.78% | 33.39% | -216.95% | -160.92% | -90.49% |
| Debt / Equity | - | 0.14x | 0.13x | 0.16x | 0.08x | 0.10x | 0.03x | 0.01x | 0.02x | 0.02x |
| Interest Coverage | - | -184.86x | -42.10x | -42.97x | - | - | - | - | - | - |
| FCF Conversion | 0.77x | 0.73x | 0.86x | 0.18x | 0.68x | 0.72x | 1.38x | 0.93x | 0.91x | 1.23x |
| Revenue Growth | -96.84% | -34.35% | 2508.44% | -96.53% | -14.76% | 4.79% | 23414.3% | -73.13% | 69.5% | 47.92% |
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Collaboration | 564K | 139.83M | 13.86M | 91.32M | 135.11M |
| Collaboration Growth | - | 24693.09% | -90.09% | 559.11% | 47.95% |
| License | 289K | - | - | 50K | 50K |
| License Growth | - | - | - | - | 0.00% |
| US Rights and Global Rights | - | - | 85.3M | - | - |
| US Rights and Global Rights Growth | - | - | - | - | - |
| Collaboration Program, US Rights | - | 24.9M | 13.9M | - | - |
| Collaboration Program, US Rights Growth | - | - | -44.18% | - | - |
Prothena Corporation plc (PRTA) reported $11.8M in revenue for fiscal year 2024. This represents a 2225% increase from $0.5M in 2011.
Prothena Corporation plc (PRTA) grew revenue by 47.9% over the past year. This is strong growth.
Prothena Corporation plc (PRTA) reported a net loss of $280.5M for fiscal year 2024.
Prothena Corporation plc (PRTA) has a return on equity (ROE) of -23.3%. Negative ROE indicates the company is unprofitable.
Prothena Corporation plc (PRTA) had negative free cash flow of $188.2M in fiscal year 2024, likely due to heavy capital investments.